Bartolome Burguera, MD
Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1093148983
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,052 of the $51,697 with a category attached, or 65.9%. 8 manufacturers reported payments, led by Medical Device Business Services, Inc. at 34.8% of the total. Reporting peaked in 2019 at $29,839 and has fallen 90.3% since, to $2,895 in 2023. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $1292.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$18K
- Novo Nordisk AS$16K
- Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C.$14K
- Novo Nordisk$2K
- Abbott$1K
- Janssen Scientific Affairs, LLC$226
- plus $148 from 2 others
Across 498 payments — averaging $6048.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$3M
- Novo Nordisk$1K
What the payments were for
- Consulting fees$34,05266%
- Travel & lodging$16,49232%
- Food & beverage$1,1402%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 14 | $17,993 |
| Novo Nordisk AS | 6 | $16,250 |
| Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C. | 8 | $14,160 |
| Novo Nordisk | 7 | $1,921 |
| Abbott | 1 | $1,000 |
| Janssen Scientific Affairs, LLC | 2 | $226 |
| Medtronic | 1 | $135 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HARMONIC Product Family$17,233
- ECHELON FLEX Stapler$13,713
- ENSEAL Product Family$13,713
- ECHELON ENDOPATH$13,696
- Endopath Xcel$13,696
- Harmonic$13,696
- ECHELON ENDOPATH Stapler$4,362
- ENDOPATH XCEL Trocar Portfolio$3,520
- ENSITE PRECISION$1,000
- Saxenda$340
- Signia$135
- XARELTO$134
- INVOKANA$134
How this compares
$51,697 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $27,959 |
| MounjaroTirzepatide | 23 | $22,993 |
| TrulicityDulaglutide | 19 | $19,810 |
| JardianceEmpagliflozin | 13 | $9,462 |
| Metformin Hcl ErMetformin Hcl | 22 | $545 |
| Bupropion Hcl | 14 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,921 | $27,95922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cleveland
- Kevin PantaloneCleveland$1.2M
- Allan KennedyCleveland$245K
- Adi MehtaCleveland$120K
- Amir HamrahianCleveland$59K
- Christian NasrCleveland$46K
- Robert ZimmermanCleveland$45K
- Mario SkugorCleveland$45K
- Bahauddin ArafahCleveland$25K
- Divya Yogi-MorrenCleveland$24K
- Vinni MakinCleveland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.